Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28359865 | 0.87 | HTR2C (0.39) | RORCHTR2CHTR2BMEN1KMT2A | |
| SCHEMBL30407118 | 0.86 | KDM4E (0.35) | ABCG2HTR2CHTR2BKDM4EMEN1 | |
| SCHEMBL1735849 | 0.79 | ABCG2 (0.32) | ABCG2HTR2CHTR2BKDM4EMEN1 | |
| SCHEMBL7048423 | 0.78 | — | — | |
| SCHEMBL9506276 | 0.77 | ABCG2 (0.30) | ABCG2 | |
| SCHEMBL29973138 | 0.76 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL30912029 | 0.75 | CA2 (0.36) | — | |
| SCHEMBL31412834 | 0.74 | CHRNB4 (0.43) | ABCG2 | |
| SCHEMBL670318 | 0.73 | ALDH1A1 (0.45) | RORCKDM4EALDH1A1 | |
| SCHEMBL5100128 | 0.72 | KDM4E (0.30) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2323734-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | Schering Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010017120-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | ADRA2C, ADRB2, ADRA2A | RORC 188/4885ABCG2 279/4885HTR2C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.